Study of Gecacitinib in the Treatment of Acute Graft-Versus-Host Disease After Failure of Ruxolitinib-containing Second-line Therapy
PHASE2Not yet recruitingINTERVENTIONAL
Enrollment
15
Participants
Timeline
Start Date
October 1, 2025
Primary Completion Date
February 1, 2027
Study Completion Date
December 1, 2027
Conditions
Acute Graft Versus Host Disease Grade II-IVAcute Graft vs Host Disease
Interventions
DRUG
Gecacitinib
Administer 50 mg twice daily for a minimum of 28 days.
All Listed Sponsors
lead
Ruijin Hospital
OTHER
NCT07197112 - Study of Gecacitinib in the Treatment of Acute Graft-Versus-Host Disease After Failure of Ruxolitinib-containing Second-line Therapy | Biotech Hunter | Biotech Hunter